Only FDA-Approved* Disease Modifying Osteoarthritis Drug (DMOAD)
Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved* DMOAD for dogs in the U.S.
Polysulfated vs. Monosulfated
Adequan® Canine contains multiple sulfur molecules. The larger number of sulfur molecules helps to inhibit the various enzymes that lead to cartilage destruction in arthritis and enhances cartilage metabolism.
Adequan® Canine delivers therapeutic drug levels to synovial joints by avoiding the digestive enzymes of the GI tract.
Adequan® Canine’s low molecular weight means it can’t be blocked from the synovial fluid by the synovial membrane.
Several studies** have demonstrated the efficacy of Adequan® Canine in controlling signs of non-infectious degenerative and/or traumatic arthritis.
* NADA #141-038, Approved by FDA
** Source: Freedom of Information - NADA #141-038; Title: Controlled Field Trial